OncoMatch/Clinical Trials/NCT07025889
IBI343 Combined With Sintilimab Plus Chemotherapy in Gastric Cancer
Is NCT07025889 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1/2 trial studies multiple treatments including IBI343 and Sintilimab for gastric cancer.
Treatment: IBI343 · Sintilimab · Oxaliplatin · S-1 — This is a Single-arm, Open-label, Phase 1b/2 Study of IBI343 Combined with Sintilimab Plus Chemotherapy in Previously Untreated, Claudin (CLDN) 18.2-positive, HER2-negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Chemotherapy
Other
Cancer type
Gastric Cancer
Biomarker criteria
Required: CLDN18 CLDN18.2-positive
histopathologically confirmed CLDN18.2-positive disease
Required: HER2 (ERBB2) overexpression (IHC 3+, or IHC 2+ and positive by in situ hybridization)
HER2-positive (defined as immunohistochemistry [IHC] 3+, or IHC 2+ and positive by in situ hybridization) disease
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Cannot have received: topoisomerase inhibitor-based antibody-drug conjugate
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT07025889 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
Does this trial require CLDN18?
Yes, CLDN18 CLDN18.2-positive is a required biomarker for enrollment.
Does this trial require ERBB2?
Yes, ERBB2 overexpression is a required biomarker for enrollment.
Is there an age limit?
Yes. Patients must be 75 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages